When a pharmaceutical importer places an order, what they are really buying is not just a product. They are buying a promise. A promise that the medicine inside each box is the same as it was described, that it was produced under controlled conditions, that it has been tested, documented, and handled correctly at every step from the factory floor to their warehouse door.
At Afif Overseas Pvt. Ltd., we take that promise seriously. Based in Ahmedabad, we have built our entire sourcing and export model around one principle: quality cannot be an afterthought. It must be the starting point.
This blog breaks down exactly what that means in practice. What certifications matter, what documentation you should expect, and why the way Afif Overseas works is specifically designed to protect you, your market, and the patients who ultimately depend on these medicines.
Between 2015 and 2025, the share of adverse inspection outcomes for Indian pharma plants fell from 12 percent to 8 percent, even as USFDA inspections became sharper and moved to surprise formats. Over the same period, global pharma saw adverse outcomes rise from 9 percent to 13 percent. Indian manufacturers are not just keeping up with global standards. They are pulling ahead.
Why Certifications Are Not Just Paperwork
In the pharmaceutical trade, a certification is not a marketing tool. It is a legal commitment backed by audits, inspections, and consequences for non-compliance. When we say our manufacturing partners are WHO-GMP certified, that means inspectors have physically visited the facility, reviewed the production lines, examined the documentation systems, and confirmed that the plant meets the World Health Organization’s standards for pharmaceutical manufacturing.
This matters enormously for importers. In most countries across the Middle East, Africa, and Asia, WHO-GMP certification from the supplying country’s national authority is a prerequisite for Ministry of Health registration. Without it, a product cannot legally enter the market. With it, the path from import clearance to pharmacy shelf is significantly smoother.
At Afif Overseas, we work only with manufacturing partners who hold the certifications relevant to your target market. We do not cut corners by sourcing from facilities that are GMP-registered on paper but have not been actively inspected. We verify. We ask for current compliance certificates, inspection histories, and we follow up.
The Certifications Our Manufacturing Partners Hold
Depending on the product category and your destination market, our manufacturing network holds certifications across the following regulatory frameworks:
- WHO-GMP: Recognised in over 100 countries and a standard requirement for government procurement tenders across the Middle East, Africa, and Southeast Asia. All our key manufacturing partners are WHO-GMP certified.
- USFDA Compliance: India hosts more USFDA-compliant pharmaceutical manufacturing plants than any country outside the United States. For importers who want the highest possible quality assurance, USFDA-compliant sourcing is available through our network.
- EU-GMP and EMA Approval: For distributors supplying markets that require European-equivalent standards, we have access to manufacturing partners with EMA and EU-GMP approvals.
- MHRA (UK): Post-Brexit, the UK Medicines and Healthcare products Regulatory Agency maintains its own approval framework. Several of our partners hold current MHRA approvals.
- Schedule M and CDSCO Compliance: India’s own Central Drugs Standard Control Organisation mandates GMP compliance under Schedule M of the Drugs and Cosmetics Rules, 1945. From January 2026, CDSCO has mandated inspections at all pharmaceutical factories to verify compliance, raising the domestic baseline significantly.
India now has over 2,000 WHO-GMP approved pharmaceutical facilities exporting to more than 150 countries. Nearly 95 percent of large-scale Indian pharmaceutical manufacturers hold international GMP certification. This is not a small subset of the industry. This is the mainstream.
What Documentation You Receive with Every Shipment
Quality on paper needs to match quality in the box. That is why documentation is not a bureaucratic inconvenience at Afif Overseas. It is a core part of what we deliver. For every shipment, you can expect the following:
- Certificate of Analysis (CoA): A batch-specific document confirming that the product has been tested and meets the specifications in the pharmacopoeial standard, whether BP, USP, or IP.
- Certificate of GMP Compliance: Issued by the relevant national regulatory authority confirming the manufacturing facility’s current compliance status.
- Product Dossier: For markets requiring Ministry of Health registration, we provide complete dossiers with formulation details, stability data, and manufacturing site information.
- Stability Reports: Confirming shelf life under real-time and accelerated conditions, essential for products shipped to tropical climates.
- Batch Manufacturing Records: Available on request for importers conducting their own due diligence or preparing for national regulatory audits.
- Packing and Shipping Documentation: Including packing lists, commercial invoices, country of origin certificates, and any market-specific regulatory import paperwork.
We understand that different markets have different documentation requirements. Iraq, Libya, and other MENA markets each have their own Ministry of Health registration protocols. Our team is experienced in preparing the correct documentation package for each specific destination so that your import clearance process is as straightforward as possible.
Cold Chain and Special Handling
For temperature-sensitive pharmaceutical products, including certain injectables, biologicals, and stability-critical formulations, quality is only preserved if the cold chain is maintained from manufacturer to destination. Afif Overseas works with freight and logistics partners who specialise in pharmaceutical cold-chain shipments, with pre-qualified packaging, GDP-compliant temperature monitoring, and proper carrier documentation.
We do not treat cold-chain compliance as optional. If a product requires controlled temperature storage and transport, we build that into the shipment plan from day one.
Our Quality Assurance Approach Is Proactive, Not Reactive
Many exporters will resolve quality issues after a complaint arrives. We prefer to prevent them entirely. Before we onboard a new manufacturing partner, we review their compliance history, audit outcomes, and current certification status. We request sample CoAs and stability data. We ask the questions that matter before your order is placed, not after it arrives.
For repeat orders, we track batch documentation to ensure consistency over time. If a manufacturing partner’s compliance status changes, we flag it immediately and work with you to find an alternative source before it disrupts your supply chain.
This approach is what we mean when we say zero compromises. It is not a slogan. It is a working method.
Talk to Us About Your Quality Requirements
Every market has specific quality and documentation standards, and we know that navigating these requirements can be complex. If you are evaluating a new pharmaceutical supplier or looking to replace a current source that has let you down on quality or documentation, we are ready to have that conversation.
Tell us what your market requires. We will tell you exactly how our network meets those requirements and share the supporting documentation that backs it up.
Contact Afif Overseas Pvt. Ltd.
Phone: +91 99790 15551 | Email: info@afifoverseas.com | Website: www.afifoverseas.com
